Renaissance Technologies’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$159K Buy
116,000
+5,600
+5% +$15.7K ﹤0.01% 2955
2025
Q4
$335K Buy
110,400
+10,300
+10% +$38.3K ﹤0.01% 2722
2025
Q3
$435K Buy
100,100
+9,500
+10% +$39.7K ﹤0.01% 2855
2025
Q2
$286K Buy
90,600
+1,800
+2% +$6.08K ﹤0.01% 3059
2025
Q1
$314K Buy
88,800
+1,500
+2% +$6.22K ﹤0.01% 2917
2024
Q4
$278K Buy
87,300
+3,300
+4% +$11.3K ﹤0.01% 3070
2024
Q3
$308K Buy
84,000
+2,200
+3% +$9.06K ﹤0.01% 2974
2024
Q2
$382K Buy
81,800
+16,100
+25% +$96.8K ﹤0.01% 2812
2024
Q1
$578K Buy
65,700
+21,900
+50% +$117K ﹤0.01% 2802
2023
Q4
$187K Buy
43,800
+5,700
+15% +$20.1K ﹤0.01% 3151
2023
Q3
$130K Sell
38,100
-6,800
-15% -$30.9K ﹤0.01% 3194
2023
Q2
$253K Buy
44,900
+20,300
+83% +$105K ﹤0.01% 3201
2023
Q1
$119K Buy
24,600
+3,500
+17% +$18.4K ﹤0.01% 3434
2022
Q4
$127K Sell
21,100
-200
-0.9% -$1K ﹤0.01% 3557
2022
Q3
$102K Sell
21,300
-800
-4% -$4.3K ﹤0.01% 3593
2022
Q2
$126K Buy
22,100
+11,400
+107% +$68K ﹤0.01% 3787
2022
Q1
$77K Buy
+10,700
New +$71.5K ﹤0.01% 3836

Other funds holding LTRN

Renaissance Technologies's LTRN Position: Q1 2026 in Review

Renaissance Technologies increased its Lantern Pharma (LTRN) stake by 5.1% in Q1 2026, buying an estimated $15.7K and bringing the position to 116,000 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #2955.

Renaissance Technologies first reported a position in LTRN in Q1 2022 and has held it in 17 quarters since. The position peaked at $578K in Q1 2024. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Renaissance Technologies held 116,000 shares of Lantern Pharma worth $159K as of Q1 2026.
  • Renaissance Technologies bought 5,600 Lantern Pharma shares in Q1 2026, an estimated $15.7K.
  • Lantern Pharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2955 holding.
  • Renaissance Technologies first reported a position in Lantern Pharma in Q1 2022 and has held it in 17 quarters since.
  • Renaissance Technologies's Lantern Pharma position peaked at $578K in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.